2-neo-Pentyl-5-methyl-1,3,4-thiadiazol | 38391-25-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-neo-Pentyl-5-methyl-1,3,4-thiadiazol
• 英文别名: 2-(2,2-dimethyl-propyl)-5-methyl-[1,3,4]thiadiazole；2-(2,2-Dimethylpropyl)-5-methyl-1,3,4-thiadiazole
• CAS: 38391-25-2
• 化学式: C₈H₁₄N₂S
• 分子量: 170.279
• InChiKey: OXRKTUHPJRVKFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3,3-dimethyl-butyric acid N'-acetyl-hydrazide 在 tetraphosphorus decasulfide 作用下， 生成 2-neo-Pentyl-5-methyl-1,3,4-thiadiazol
  参考文献：
  名称：

  Lund,H., Acta Chemica Scandinavica (1947), 1973, vol. 27, p. 391 - 395

  摘要：

  DOI：

文献信息

• 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS
  申请人：NOVARTIS AG

  公开号：US20210107889A1

  公开（公告）日：2021-04-15

  Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 5 , and R 7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

  本文提供了根据式（I）或其药学上可接受的盐的化合物，其中R1、R2、R3、R5和R7在此处被定义。本文还提供了包含式（I）化合物的药物组合物，以及将这些化合物用作M4受体激动剂的用途。
• Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US11214563B2

  公开（公告）日：2022-01-04

  Substituted PYRAZOLO-PYRAZINES as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.

  作为 GluN2B 受体配体的被取代的吡唑啉类化合物。此类化合物可用于调节 GluN2B 受体，以及用于治疗由 GluN2B 受体活性介导的疾病状态、紊乱和病症的药物组合物和方法。
• Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors
  申请人：Pfizer Inc.

  公开号：US11312713B2

  公开（公告）日：2022-04-26

  The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

  本发明提供了式(I)的新型咪唑并[4,5-c]喹啉衍生物及其药学上可接受的盐 I 其中 R1、R2 和 R3 如说明书中所定义。本发明还涉及包含式 I 化合物的药物组合物，以及这些化合物在治疗与 LRRK2 有关的疾病中的用途，例如神经退行性疾病，包括帕金森病或阿尔茨海默病、癌症、克罗恩病或麻风病。
• Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US11530210B2

  公开（公告）日：2022-12-20

  Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.

  取代的吡唑并吡啶作为 GluN2B 受体配体。此类化合物可用于调节 GluN2B 受体，以及用于治疗由 GluN2B 受体活性介导的疾病状态、紊乱和病症的药物组合物和方法。
• SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20200392113A1

  公开（公告）日：2020-12-17

  Substituted PYRAZOLO-PYRAZINES as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.